⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KALA News
KALA BIO, Inc. Common Stock
KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
globenewswire.com
KALA
KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint
globenewswire.com
KALA